Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
26 juin 2024 10h50 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7...
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity
24 juin 2024 14h16 HE
|
Novo Nordisk A/S
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. ...
Novo Nordisk A/S - share repurchase programme
24 juin 2024 08h55 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
23 juin 2024 01h01 HE
|
Novo Nordisk A/S
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo...
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
18 juin 2024 08h00 HE
|
Novo Nordisk A/S
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety...
Novo Nordisk A/S - share repurchase programme
17 juin 2024 08h26 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
10 juin 2024 08h15 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
03 juin 2024 10h05 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
27 mai 2024 08h49 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
17 mai 2024 10h20 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...